Stock Report

All about this stock under one free report Last Updated: 03-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Medpace Holdings (MEDP) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$592.28

up-down-arrow $9.07 (1.56%)

As on 02-Sep-2026 14:37EDT

Market cap

info icon

$16,765 Mln

Revenue (TTM)

info icon

$2,782 Mln

P/E Ratio

info icon

35.2

P/B Ratio

info icon

39.3

Div. Yield

info icon

0 %

Edit peer-selector-edit
Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
Market cap ($ Mln)
 16,765 16,261 13,492 11,994 11,957
Revenue ($ Mln)
 2,782 1,054 2,436 670 1,664
Net Profit ($ Mln)
 491.50 755.85 860.62 -319.95 413.60
Net Margin (%)
 17.67 71.69 35.33 -47.79 24.86
RoE (%)
 110.09 -- 42.98 -71.14 430.03
Price to Earnings
 35.25 19.00 17.40 -- 30.89
Price-To-Book
 39.29 9.76 7.42 26.87 84.52

Income Statement ($ Mln)

Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
Operating Revenue arrow
2,782.29 1,054.37 2,435.92 669.50 1,663.74
Cost of Revenue arrow
1,982.07 103.47 85.67 19.14 363.07
Gross Profit arrow
760.62 588.53 2,236.43 829.45 1,091.18
Operating Expenses arrow
216.81 841.45 1,378.74 895.93 356.18
Operating Profit (EBIT) arrow
583.40 109.45 971.51 -226.44 944.49
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
598.92 101.11 1,035.47 -252.08 583.34
Provision for Tax arrow
107.42 -654.74 174.84 20.05 169.74
Profit after Tax (Net Income) arrow
491.50 755.85 860.62 -319.95 413.60
Minority Interest arrow
0.00 0.00 0.00 -47.83 0.00
Consolidated Profit arrow
0.00 0.00 0.00 0.00 0.00

Liabilities ($ Mln)

Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
Shareholder's Funds arrow
433.86 1,435.90 1,843.76 465.53 143.54
Minority Interest arrow
0.00 0.00 0.00 -47.83 0.00
Non-Current Liabilities arrow
187.89 384.48 288.55 1,362.63 2,089.43
Current Liabilities arrow
1,435.43 464.70 361.93 283.35 344.44
Total Liabilities arrow
1,975.47 1,302.02 2,844.42 1,385.30 2,525.32

Assets ($ Mln)

Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
Non-Current Assets arrow
1,006.90 895.24 1,243.41 440.60 1,644.38
Current Assets arrow
1,050.29 1,389.84 1,250.82 1,671.41 933.02
Total Assets arrow
1,975.47 1,302.02 2,844.42 1,385.30 2,525.32
Total Debt* arrow
120.10 449.89 165.93 864.07 2,146.65
Net Current Assets arrow
-385.14 0.00 888.90 1,388.07 588.59

Cashflow ($ Mln)

Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
Cash From Operating Activities arrow
713.22 51.77 884.27 179.55 651.56
Cash Flow from Investing Activities arrow
-31.14 -8.15 350.44 -129.29 -545.81
Cash from Financing Activities arrow
-860.39 34.89 -969.59 74.01 -85.17
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
ROCE (%) arrow
53.56 -30.01 32.82 -0.17 15.61
ROE (%) arrow
110.09 163.18 42.98 -71.14 430.03
ROA (%) arrow
15.64 26.53 29.32 -16.12 16.19
EBIT Margin (%) arrow
21.13 5.73 31.04 -0.77 36.28
Net Margin (%) arrow
17.67 71.69 35.33 -47.79 24.86
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
Revenue Growth (%) arrow
24.67 114.85 9.23 12.22 41.15
EBIT Growth (%) arrow
18.70 136.39 -3.99 93.17 -14.99
Net Profit Growth (%) arrow
17.50 378.76 42.89 -115.58 -25.78
EPS Growth (%) arrow
26.84 353.27 50.42 -73.87 -23.48
Book Value Growth (%) arrow
164.02 816.12 -0.70 -13.57 -55.81

Valuation Ratios

 Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
Price / Earnings arrow
36.06 -59.76 15.79 -2,869.63 24.99
Price / Book Value arrow
35.44 -80.42 5.72 10.04 162.23
Dividend Yield (%) arrow
-- -- -- -- --
EV/EBITDA arrow
28.08 -121.54 12.44 25.04 17.31
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
Debt to Equity arrow
0.00 0.00 0.00 1.77 13.50
Short term debt to equity ratio arrow
0.00 0.05 0.00 0.09 1.46
Current Ratio arrow
0.73 2.99 3.46 5.90 2.71
Quick Ratio arrow
0.73 2.32 3.38 5.90 2.31
Interest Coverage arrow
-- 1.62 -- -1.72 29.73

Operating Efficiency Ratios

 Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Arrowhead Pharmaceuticals (ARWR) Halozyme Therapeutics (HALO)
Debtors to sales (%) arrow
15.88 21.25 13.74 1.28 27.40
Asset Turnover arrow
0.89 0.37 0.83 0.34 0.65
Receivable days arrow
50.42 85.52 43.48 1.50 98.04
Inventory Days arrow
-- 1,056.70 96.17 -- 190.34
Payable days arrow
6.26 331.01 147.97 221.81 18.62
Cash Conversion Cycle arrow
-- 811.21 -8.32 -- 269.75
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...